207940 — Samsung Biologics Co Share Price
0.000.00%
Last trade - 00:00- KR₩74tn
- KR₩74tn
- KR₩5tn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 51.33 | ||
| PEG Ratio (f) | 3.14 | ||
| EPS Growth (f) | 19.52% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.76 | ||
| Price to Tang. Book | 13.8 | ||
| Price to Free Cashflow | 261.47 | ||
| Price to Sales | 16.2 | ||
| EV to EBITDA | 39.76 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.33% | ||
| Return on Equity | 10.45% | ||
| Operating Margin | 27.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,164,776.87 | 1,568,006.93 | 3,001,295.2 | 3,694,588.77 | 4,547,322.18 | 5,533,364 | 6,407,857 | 45.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +19.74 | +63.54 | +80.01 | +12.25 | +32.36 | +18.55 | +21.28 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in the production of antibody drugs. The Company operates through two segments. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides biopharmaceutical contract manufacturing and cell line development services. The Biopharmaceutical Development and Commercialization segment primarily engages in the development and commercialization of biosimilars.
Directors
- John Rim PRE (59)
- Dong Jung Kim CFO (56)
- John Kim VPR (54)
- Gyu Seong Lee VPR (60)
- Gwang Hun Yoon VPR (64)
- James Choi MDR (52)
- In Gyu Kim MDR (55)
- Sam Machour MDR (58)
- James Park MDR (54)
- Ho Yeol Yoon MDR (57)
- Yong Ho Ahn OTH (53)
- Regina Choi OTH (50)
- Wan Goo Hwang OTH (49)
- Yong Hwan Jin OTH (54)
- Gi Jung Kim OTH (51)
- Yong Sin Kim OTH (56)
- Chung Wu Lee OTH (51)
- Hyeong Wu Moon OTH (51)
- Se Gang Park OTH (46)
- Sang Won Seo OTH (42)
- Byung Hwa Shim OTH (53)
- Daniel Slone OTH (70)
- Eun Yeong Yang OTH (46)
- Gyeong Sim Yim OTH (47)
- Hui Gyun Yim OTH (45)
- Tae Han Kim DRC (63)
- Sun Jo Gwon NID (55)
- Geun Nyeong Huh NID (65)
- Seok Wu Jung NID (58)
- Eunice Kyunghee Kim NID (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 22nd, 2011
- Public Since
- November 10th, 2016
- No. of Employees
- 2,587
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 71,174,000
- Address
- 300, Songdo bio-daero, Yeonsu-gu, INCHEON, 21987
- Web
- https://samsungbiologics.com/
- Phone
- +82 324553114
- Auditors
- Samil Accounting Corp.
Upcoming Events for 207940
Q3 2025 Samsung Biologics Co Ltd Earnings Release
Similar to 207940
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Samsung Biologics Co share price?
As of Today at 23:03 UTC, shares in Samsung Biologics Co are trading at KR₩1,035,000. This share price information is delayed by 15 minutes.
How has the Samsung Biologics Co share price performed this year?
Shares in Samsung Biologics Co last closed at KR₩1,035,000 and the price had moved by +32.69% over the past 365 days. In terms of relative price strength the Samsung Biologics Co share price has outperformed the FTSE Developed Asia Pacific Index by +34.21% over the past year.
What are the analyst and broker recommendations for Samsung Biologics Co?
The overall consensus recommendation for Samsung Biologics Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Samsung Biologics Co dividend yield?
Samsung Biologics Co does not currently pay a dividend.
Does Samsung Biologics Co pay a dividend?
Samsung Biologics Co does not currently pay a dividend.
When does Samsung Biologics Co next pay dividends?
Samsung Biologics Co does not currently pay a dividend.
How do I buy Samsung Biologics Co shares?
To buy shares in Samsung Biologics Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Samsung Biologics Co?
As of the previous close price of KR₩1,035,000, shares in Samsung Biologics Co had a market capitalisation of KR₩74tn.
Where are Samsung Biologics Co shares listed?
Here are the trading details for Samsung Biologics Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 207940
What kind of share is Samsung Biologics Co?
Based on an overall assessment of its quality, value and momentum Samsung Biologics Co is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Samsung Biologics Co share price forecast for 2025?
The analyst consensus target price for shares in Samsung Biologics Co is KR₩1,319,100. That is 27.45% above the last closing price of KR₩1,035,000.
Analysts covering Samsung Biologics Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩18,887 for the next financial year.
Find out moreWhat is the trend in the Samsung Biologics Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Samsung Biologics Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +3.37%.
As of the last closing price of KR₩1,035,000, shares in Samsung Biologics Co were trading +3.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Samsung Biologics Co PE Ratio?
The Samsung Biologics Co PE ratio based on its reported earnings over the past 12 months is 51.33. The shares last closed at KR₩1,035,000.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Samsung Biologics Co?
Samsung Biologics Co's management team is headed by:
- John Rim - PRE
- Dong Jung Kim - CFO
- John Kim - VPR
- Gyu Seong Lee - VPR
- Gwang Hun Yoon - VPR
- James Choi - MDR
- In Gyu Kim - MDR
- Sam Machour - MDR
- James Park - MDR
- Ho Yeol Yoon - MDR
- Yong Ho Ahn - OTH
- Regina Choi - OTH
- Wan Goo Hwang - OTH
- Yong Hwan Jin - OTH
- Gi Jung Kim - OTH
- Yong Sin Kim - OTH
- Chung Wu Lee - OTH
- Hyeong Wu Moon - OTH
- Se Gang Park - OTH
- Sang Won Seo - OTH
- Byung Hwa Shim - OTH
- Daniel Slone - OTH
- Eun Yeong Yang - OTH
- Gyeong Sim Yim - OTH
- Hui Gyun Yim - OTH
- Tae Han Kim - DRC
- Sun Jo Gwon - NID
- Geun Nyeong Huh - NID
- Seok Wu Jung - NID
- Eunice Kyunghee Kim - NID